With Novavax vaccine deal under its belt, SK Bioscience plots out March IPO on the Korean exchange
It pays to be in the Covid-19 vaccine manufacturing business.
Shortly after it announced an expanded deal to produce 40 million doses of Novavax’s Covid …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
